GCP
AVNR

GSA Capital Partners’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

GSA Capital Partners’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-39,628
Closed -$472K – 2080
2014
Q3 		$472K Sell
39,628
-12,700
-24% -$86.7K 0.02% 969
2014
Q2 		$295K Buy
+52,328
New +$241K 0.01% 1433
2014
Q1 		– Sell
-36,546
Closed -$123K – 1999
2013
Q4 		$123K Buy
+36,546
New +$151K 0.01% 1548

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

GSA Capital Partners's AVNR Position: Q4 2014 in Review

GSA Capital Partners sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 39,628 shares — an estimated $472K sold.

GSA Capital Partners first reported a position in AVNR in Q4 2013 and held it in 3 quarters. The position peaked at $472K in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • GSA Capital Partners reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • GSA Capital Partners sold 39,628 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $472K.
  • GSA Capital Partners first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q4 2013 and held it in 3 quarters.
  • GSA Capital Partners's AVANIR PHARMACEUTICALS, INC CL A position peaked at $472K in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on GSA Capital Partners's 13F filing for Q4 2014, filed 5 Feb 2015.